{
  "variants": [
    {
      "variant": "LRRK2 G2019S",
      "steps": {
        "step1": {
          "description": "The paper establishes that LRRK2 mutations cause Parkinson's disease (PD) and focus on kinase activity as a key functional mechanism.",
          "status": "Met"
        },
        "step2": {
          "description": "The KESTREL screen assay is directly relevant to the disease mechanism (kinase activity of LRRK2).",
          "status": "Met"
        },
        "step3": {
          "substep3a": {
            "description": "The paper does not explicitly mention controls (e.g., wild-type LRRK2 or other variants as positive/negative controls) in the kinase activity assays.",
            "status": "Not Met"
          },
          "substep3b": {
            "description": "The KESTREL screen is a novel method for identifying substrates but is not explicitly validated as a standard assay in the abstract. No references to prior validation or commercial kits are provided.",
            "status": "Not Met"
          },
          "substep3c": {
            "description": "No variant controls (e.g., known pathogenic/benign variants) are explicitly mentioned in the abstract for this specific assay.",
            "status": "Not Met"
          }
        },
        "step4": {
          "substep4a": {
            "description": "No statistical analyses, p-values, or OddsPath values are reported in the abstract.",
            "status": "Not Met"
          },
          "substep4b": {
            "description": "The study tested 9 variants, but the number of explicitly identified benign/pathogenic controls is unclear. Assuming <10 controls, evidence is 'supporting'.",
            "status": "Met"
          }
        }
      },
      "evidence": {
        "type": "PS3_supporting",
        "rationale": "G2019S is a well-known pathogenic mutation that stimulates kinase activity. The study shows its effect, but lacks controls and statistical validation, leading to 'supporting' strength."
      }
    },
    {
      "variant": "LRRK2 R1941H",
      "steps": {
        "step1": {
          "description": "The paper establishes that LRRK2 mutations cause PD and focus on kinase activity as a key functional mechanism.",
          "status": "Met"
        },
        "step2": {
          "description": "The KESTREL screen assay is directly relevant to the disease mechanism (kinase activity of LRRK2).",
          "status": "Met"
        },
        "step3": {
          "substep3a": {
            "description": "The paper does not explicitly mention controls (e.g., wild-type LRRK2 or other variants as positive/negative controls) in the kinase activity assays.",
            "status": "Not Met"
          },
          "substep3b": {
            "description": "The KESTREL screen is a novel method for identifying substrates but is not explicitly validated as a standard assay in the abstract. No references to prior validation or commercial kits are provided.",
            "status": "Not Met"
          },
          "substep3c": {
            "description": "No variant controls (e.g., known pathogenic/benign variants) are explicitly mentioned in the abstract for this specific assay.",
            "status": "Not Met"
          }
        },
        "step4": {
          "substep4a": {
            "description": "No statistical analyses, p-values, or OddsPath values are reported in the abstract.",
            "status": "Not Met"
          },
          "substep4b": {
            "description": "The study tested 9 variants, but the number of explicitly identified benign/pathogenic controls is unclear. Assuming <10 controls, evidence is 'supporting'.",
            "status": "Met"
          }
        }
      },
      "evidence": {
        "type": "BS3_supporting",
        "rationale": "R1941H inhibits kinase activity. The study shows this effect, but lacks controls and statistical validation, leading to 'supporting' strength. Inhibition may suggest benign or pathogenic depending on context, but no explicit classification is provided."
      }
    },
    {
      "variant": "LRRK2 I2012T",
      "steps": {
        "step1": {
          "description": "The paper establishes that LRRK2 mutations cause PD and focus on kinase activity as a key functional mechanism.",
          "status": "Met"
        },
        "step2": {
          "description": "The KESTREL screen assay is directly relevant to the disease mechanism (kinase activity of LRRK2).",
          "status": "Met"
        },
        "step3": {
          "substep3a": {
            "description": "The paper does not explicitly mention controls (e.g., wild-type LRRK2 or other variants as positive/negative controls) in the kinase activity assays.",
            "status": "Not Met"
          },
          "substep3b": {
            "description": "The KESTREL screen is a novel method for identifying substrates but is not explicitly validated as a standard assay in the abstract. No references to prior validation or commercial kits are provided.",
            "status": "Not Met"
          },
          "substep3c": {
            "description": "No variant controls (e.g., known pathogenic/benign variants) are explicitly mentioned in the abstract for this specific assay.",
            "status": "Not Met"
          }
        },
        "step4": {
          "substep4a": {
            "description": "No statistical analyses, p-values, or OddsPath values are reported in the abstract.",
            "status": "Not Met"
          },
          "substep4b": {
            "description": "The study tested 9 variants, but the number of explicitly identified benign/pathogenic controls is unclear. Assuming <10 controls, evidence is 'supporting'.",
            "status": "Met"
          }
        }
      },
      "evidence": {
        "type": "BS3_supporting",
        "rationale": "I2012T inhibits kinase activity. The study shows this effect, but lacks controls and statistical validation, leading to 'supporting' strength. Inhibition may suggest benign or pathogenic depending on context, but no explicit classification is provided."
      }
    },
    {
      "variant": "LRRK2 I2020T",
      "steps": {
        "step1": {
          "description": "The paper establishes that LRRK2 mutations cause PD and focus on kinase activity as a key functional mechanism.",
          "status": "Met"
        },
        "step2": {
          "description": "The KESTREL screen assay is directly relevant to the disease mechanism (kinase activity of LRRK2).",
          "status": "Met"
        },
        "step3": {
          "substep3a": {
            "description": "The paper does not explicitly mention controls (e.g., wild-type LRRK2 or other variants as positive/negative controls) in the kinase activity assays.",
            "status": "Not Met"
          },
          "substep3b": {
            "description": "The KESTREL screen is a novel method for identifying substrates but is not explicitly validated as a standard assay in the abstract. No references to prior validation or commercial kits are provided.",
            "status": "Not Met"
          },
          "substep3c": {
            "description": "No variant controls (e.g., known pathogenic/benign variants) are explicitly mentioned in the abstract for this specific assay.",
            "status": "Not Met"
          }
        },
        "step4": {
          "substep4a": {
            "description": "No statistical analyses, p-values, or OddsPath values are reported in the abstract.",
            "status": "Not Met"
          },
          "substep4b": {
            "description": "The study tested 9 variants, but the number of explicitly identified benign/pathogenic controls is unclear. Assuming <10 controls, evidence is 'supporting'.",
            "status": "Met"
          }
        }
      },
      "evidence": {
        "type": "BS3_supporting",
        "rationale": "I2020T inhibits kinase activity. The study shows this effect, but lacks controls and statistical validation, leading to 'supporting' strength. Inhibition may suggest benign or pathogenic depending on context, but no explicit classification is provided."
      }
    },
    {
      "variant": "LRRK2 G2385R",
      "steps": {
        "step1": {
          "description": "The paper establishes that LRRK2 mutations cause PD and focus on kinase activity as a key functional mechanism.",
          "status": "Met"
        },
        "step2": {
          "description": "The KESTREL screen assay is directly relevant to the disease mechanism (kinase activity of LRRK2).",
          "status": "Met"
        },
        "step3": {
          "substep3a": {
            "description": "The paper does not explicitly mention controls (e.g., wild-type LRRK2 or other variants as positive/negative controls) in the kinase activity assays.",
            "status": "Not Met"
          },
          "substep3b": {
            "description": "The KESTREL screen is a novel method for identifying substrates but is not explicitly validated as a standard assay in the abstract. No references to prior validation or commercial kits are provided.",
            "status": "Not Met"
          },
          "substep3c": {
            "description": "No variant controls (e.g., known pathogenic/benign variants) are explicitly mentioned in the abstract for this specific assay.",
            "status": "Not Met"
          }
        },
        "step4": {
          "substep4a": {
            "description": "No statistical analyses, p-values, or OddsPath values are reported in the abstract.",
            "status": "Not Met"
          },
          "substep4b": {
            "description": "The study tested 9 variants, but the number of explicitly identified benign/pathogenic controls is unclear. Assuming <10 controls, evidence is 'supporting'.",
            "status": "Met"
          }
        }
      },
      "evidence": {
        "type": "BS3_supporting",
        "rationale": "G2385R inhibits kinase activity. The study shows this effect, but lacks controls and statistical validation, leading to 'supporting' strength. Inhibition may suggest benign or pathogenic depending on context, but no explicit classification is provided."
      }
    },
    {
      "variant": "LRRK2 R1941H",
      "steps": {
        "step1": {
          "description": "The paper establishes that LRRK2 mutations cause PD and focus on kinase activity as a key functional mechanism.",
          "status": "Met"
        },
        "step2": {
          "description": "The KESTREL screen assay is directly relevant to the disease mechanism (kinase activity of LRRK2).",
          "status": "Met"
        },
        "step3": {
          "substep3a": {
            "description": "The paper does not explicitly mention controls (e.g., wild-type LRRK2 or other variants as positive/negative controls) in the kinase activity assays.",
            "status": "Not Met"
          },
          "substep3b": {
            "description": "The KESTREL screen is a novel method for identifying substrates but is not explicitly validated as a standard assay in the abstract. No references to prior validation or commercial kits are provided.",
            "status": "Not Met"
          },
          "substep3c": {
            "description": "No variant controls (e.g., known pathogenic/benign variants) are explicitly mentioned in the abstract for this specific assay.",
            "status": "Not Met"
          }
        },
        "step4": {
          "substep4a": {
            "description": "No statistical analyses, p-values, or OddsPath values are reported in the abstract.",
            "status": "Not Met"
          },
          "substep4b": {
            "description": "The study tested 9 variants, but the number of explicitly identified benign/pathogenic controls is unclear. Assuming <10 controls, evidence is 'supporting'.",
            "status": "Met"
          }
        }
      },
      "evidence": {
        "type": "BS3_supporting",
        "rationale": "R1941H inhibits kinase activity. The study shows this effect, but lacks controls and statistical validation, leading to 'supporting' strength. Inhibition may suggest benign or pathogenic depending on context, but no explicit classification is provided."
      }
    },
    {
      "variant": "LRRK2 R1941H",
      "steps": {
        "step1": {
          "description": "The paper establishes that LRRK2 mutations cause PD and focus on kinase activity as a key functional mechanism.",
          "status": "Met"
        },
        "step2": {
          "description": "The KESTREL screen assay is directly relevant to the disease mechanism (kinase activity of LRRK2).",
          "status": "Met"
        },
        "step3": {
          "substep3a": {
            "description": "The paper does not explicitly mention controls (e.g., wild-type LRRK2 or other variants as positive/negative controls) in the kinase activity assays.",
            "status": "Not Met"
          },
          "substep3b": {
            "description": "The KESTREL screen is a novel method for identifying substrates but is not explicitly validated as a standard assay in the abstract. No references to prior validation or commercial kits are provided.",
            "status": "Not Met"
          },
          "substep3c": {
            "description": "No variant controls (e.g., known pathogenic/benign variants) are explicitly mentioned in the abstract for this specific assay.",
            "status": "Not Met"
          }
        },
        "step4": {
          "substep4a": {
            "description": "No statistical analyses, p-values, or OddsPath values are reported in the abstract.",
            "status": "Not Met"
          },
          "substep4b": {
            "description": "The study tested 9 variants, but the number of explicitly identified benign/pathogenic controls is unclear. Assuming <10 controls, evidence is 'supporting'.",
            "status": "Met"
          }
        }
      },
      "evidence": {
        "type": "BS3_supporting",
        "rationale": "R1941H inhibits kinase activity. The study shows this effect, but lacks controls and statistical validation, leading to 'supporting' strength. Inhibition may suggest benign or pathogenic depending on context, but no explicit classification is provided."
      }
    },
    {
      "variant": "LRRK2 I2020T",
      "steps": {
        "step1": {
          "description": "The paper establishes that LRRK2 mutations cause PD and focus on kinase activity as a key functional mechanism.",
          "status": "Met"
        },
        "step2": {
          "description": "The KESTREL screen assay is directly relevant to the disease mechanism (kinase activity of LRRK2).",
          "status": "Met"
        },
        "step3": {
          "substep3a": {
            "description": "The paper does not explicitly mention controls (e.g., wild-type LRRK2 or other variants as positive/negative controls) in the kinase activity assays.",
            "status": "Not Met"
          },
          "substep3b": {
            "description": "The KESTREL screen is a novel method for identifying substrates but is not explicitly validated as a standard assay in the abstract. No references to prior validation or commercial kits are provided.",
            "status": "Not Met"
          },
          "substep3c": {
            "description": "No variant controls (e.g., known pathogenic/benign variants) are explicitly mentioned in the abstract for this specific assay.",
            "status": "Not Met"
          }
        },
        "step4": {
          "substep4a": {
            "description": "No statistical analyses, p-values, or OddsPath values are reported in the abstract.",
            "status": "Not Met"
          },
          "substep4b": {
            "description": "The study tested 9 variants, but the number of explicitly identified benign/pathogenic controls is unclear. Assuming <10 controls, evidence is 'supporting'.",
            "status": "Met"
          }
        }
      },
      "evidence": {
        "type": "BS3_supporting",
        "rationale": "I2020T inhibits kinase activity. The study shows this effect, but lacks controls and statistical validation, leading to 'supporting' strength. Inhibition may suggest benign or pathogenic depending on context, but no explicit classification is provided."
      }
    }
  ]
}